Needham Releases a Buy Rating on Aerie Pharma (AERI)

Needham analyst Serge Belanger assigned a Buy rating to Aerie Pharma (AERIResearch Report) today and set a price target of $26.00. The company’s shares closed last Wednesday at $18.34.

According to, Belanger is a 4-star analyst with an average return of 9.1% and a 49.5% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Collegium Pharmaceutical, and KalVista Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aerie Pharma with a $27.25 average price target, implying a 44.6% upside from current levels. In a report issued on April 5, Mizuho Securities also maintained a Buy rating on the stock with a $28.00 price target.

See today’s analyst top recommended stocks >>

Based on Aerie Pharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $24.68 million and GAAP net loss of $46.14 million. In comparison, last year the company earned revenue of $24.66 million and had a GAAP net loss of $55.06 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.